Navigation Links
Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
Date:2/4/2010

RESEARCH TRIANGLE PARK, N.C., Feb. 4 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Gwendolyn Powell Painter, M.D., M.P.H., has joined the company as Chief Medical Officer.  

Dr. Painter has more than 20 years of experience in the pharmaceutical industry, including work in clinical development, clinical safety and pharmacovigilance, and occupational and environmental medicine.  In her role as Chief Medical Officer, Dr. Painter will be responsible for clinical strategy and development of Chimerix's proprietary antiviral medicines addressing life-threatening diseases.  Dr. Painter has been working with Chimerix since 2002 in a consulting capacity, providing medical oversight and clinical consulting.  

"We are delighted to have Wendy join our leadership team.  Her extensive background in all phases of antiviral drug development has been and will be invaluable as we advance our pipeline through the clinical trials process," said Kenneth I. Moch, Chimerix's Chief Operating Officer.  "Wendy has been a vital force in the development of our broad-spectrum antiviral candidate CMX001."

Dr. Painter has an extensive background in drug development at a number of biotechnology and pharmaceutical companies.  Her experience includes having served as Medical Director at GlaxoSmithKline (GSK) where she had responsibility for worldwide antiviral clinical safety.  While there, she was involved in a number of antiviral Investigational New Drug (IND) applications and New Drug Application (NDA) submissions to the U.S. Food and Drug Administration.  Subsequently, she provided expert medical consulting to a range of biotechnology and pharmaceutical companies regarding drug development.  Dr. Painter earned an M.S. in Organic Chemistry at Emory University and an M.D. degree at the University of Miami School Of Medicine.  She later obtained a Master of Public Health degree in Epidemiology at the University of North Carolina at Chapel Hill and completed a fellowship in occupational medicine at Duke University where she maintains an academic appointment.

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, in addition to significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.

RELATED LINKS
http://www.chimerix-inc.com

'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
6. KGI Names Kerry Howell Vice President for Advancement
7. Vical Names Andrew de Guttadauro Vice President, Corporate Development
8. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
9. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
10. CryoLife Names Philip Theodore as Vice President, General Counsel
11. Genstar Names Michael Hurt to Its Strategic Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):